ARS PharmaceuticalsSPRY

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis.

$686.2M

Market Cap • 02/06/2023

2016

(7 years ago)
Founded

2022

(1 year ago)
IPO

San Diego

Headquarters • California

20

Employees 2022

Valuation

Valuation Indicators
YearEquityRevenueEBITDAFin. Res.Net Inc.Net Mar.ROECashDebtN.D. / EBITDAOCFCAPEXFCFFreeDiv.
03/23 TTM2611-470-42LL2650L-460193-460

The values above are represented in USD and the scale is in millions—10.000 is the equivalent of 10 billions. L inside the table means Loss.